Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Jonathan Zalevsky net worth and biography

Jonathan Zalevsky Biography and Net Worth

Insider of Nektar Therapeutics

Jonathan Zalevsky was appointed Nektar’s Chief Research & Development Officer in October 2019 to lead all aspects of the R&D organization, including research, clinical development, regulatory affairs, and biologics process development. Dr. Zalevsky joined the Company in 2015 and has served as our Chief Scientific Officer since 2017. During his tenure at Nektar, Dr. Zalevsky’s expertise in immunology, and across biological modalities and therapeutic areas, has helped fuel the growth of the company’s immuno-oncology and immunology pipeline. Dr. Zalevsky led the early development for bempegaldeskleukin and NKTR-358.

Prior to joining Nektar, Dr. Zalevsky was Global Vice President and Head of the Inflammation Drug Discovery Unit at Takeda Pharmaceuticals. As the leading immunologist for Takeda, he was responsible for an immunology pipeline that spanned from early target discovery to late-stage development and marketed products. Prior to his work at Takeda, Dr. Zalevsky worked in research and development at Xencor, where he oversaw the discovery and development of Xencor's first four clinical-stage assets.

Dr. Zalevsky received his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco. He received dual B.S. degrees in Biochemistry and Molecular, Cellular, and Developmental Biology from the University of Colorado at Boulder.

What is Jonathan Zalevsky's net worth?: The estimated net worth of Jonathan Zalevsky is at least $375,010.38 as of February 20th, 2024. Dr. Zalevsky owns 265,025 shares of Nektar Therapeutics stock worth more than $375,010 as of April 23rd. This net worth evaluation does not reflect any other assets that Dr. Zalevsky may own. Additionally, Dr. Zalevsky receives an annual salary of $1,250,000.00 as Insider at Nektar Therapeutics. Learn More about Jonathan Zalevsky's net worth.
How old is Jonathan Zalevsky?: Dr. Zalevsky is currently 49 years old. There are 4 older executives and no younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Mr. Howard W. Robin, CEO, President & Director, who is 71 years old. Learn More on Jonathan Zalevsky's age.
What is Jonathan Zalevsky's salary?: As the Insider of Nektar Therapeutics, Dr. Zalevsky earns $1,250,000.00 per year. The highest earning executive at Nektar Therapeutics is Mr. Howard W. Robin, CEO, President & Director, who commands a salary of $1,830,000.00 per year. Learn More on Jonathan Zalevsky's salary.
How do I contact Jonathan Zalevsky?: The corporate mailing address for Dr. Zalevsky and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Jonathan Zalevsky's contact information.
Has Jonathan Zalevsky been buying or selling shares of Nektar Therapeutics?: Jonathan Zalevsky has not been actively trading shares of Nektar Therapeutics within the last three months. Most recently, Jonathan Zalevsky sold 9,014 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $0.68, for a transaction totalling $6,129.52. Following the completion of the sale, the insider now directly owns 265,025 shares of the company's stock, valued at $180,217. Learn More on Jonathan Zalevsky's trading history.
Who are Nektar Therapeutics' active insiders?: Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.
Are insiders buying or selling shares of Nektar Therapeutics?: During the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 152,782 shares worth more than $99,202.16. The most recent insider tranaction occured on February, 20th when insider Jonathan Zalevsky sold 9,014 shares worth more than $6,129.52. Insiders at Nektar Therapeutics own 3.1% of the company. Learn More about insider trades at Nektar Therapeutics.
Information on this page was last updated on 2/20/2024.

Jonathan Zalevsky Insider Trading History at Nektar Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2024	Sell	9,014	$0.68	$6,129.52	265,025
11/17/2023	Sell	9,646	$0.49	$4,726.54	274,039
8/16/2023	Sell	9,703	$0.78	$7,568.34	283,685
5/16/2023	Sell	9,791	$0.72	$7,049.52	293,388
2/16/2023	Sell	10,484	$3.00	$31,452.00	303,179
11/16/2022	Sell	13,460	$3.57	$48,052.20	313,663
8/18/2022	Sell	73,716	$4.65	$342,779.40	327,123
8/16/2022	Sell	10,560	$4.76	$50,265.60	400,839
5/16/2022	Sell	21,673	$3.95	$85,608.35	276,399
2/16/2022	Sell	10,912	$10.95	$119,486.40
8/16/2021	Sell	7,662	$13.83	$105,965.46
5/17/2021	Sell	31,111	$18.30	$569,331.30	235,065
11/23/2020	Sell	16,380	$16.40	$268,632.00	250,317
8/17/2020	Sell	26,200	$19.67	$515,354.00	296,315
2/18/2020	Sell	4,774	$22.35	$106,698.90	327,073
11/18/2019	Sell	3,960	$17.97	$71,161.20	291,697

Jonathan Zalevsky Buying and Selling Activity at Nektar Therapeutics

Nektar Therapeutics Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Today's Range

Now: $1.42

$1.31

$1.43

50 Day Range

MA: $0.99

$0.66

$1.67

2 Week Range

Now: $1.42

$0.41

$1.75

Volume

1,099,906 shs

Average Volume

2,180,346 shs

Market Capitalization

$260.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

From Banyan Hill Publishing | Ad

See how you can invest alongside him

Jonathan Zalevsky Biography and Net Worth

What is Jonathan Zalevsky's net worth?

How old is Jonathan Zalevsky?

What is Jonathan Zalevsky's salary?

How do I contact Jonathan Zalevsky?

Has Jonathan Zalevsky been buying or selling shares of Nektar Therapeutics?

Who are Nektar Therapeutics' active insiders?

Are insiders buying or selling shares of Nektar Therapeutics?